Huaren Pharmaceutical Co (300110) Fair Value & Analysis
Healthcare · CN · Market cap 3.1B CNY
Fair value as of: Jun 24, 2026
Analysis
Huaren Pharmaceutical Co (300110) currently trades at ¥2.59, while our model-based Fair Value estimate is ¥2.88 — implying the stock looks roughly 11.2% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therapeutic infusion products for blood volume expansion, hemostasis, nervous and circulatory systems, anti-infection, anti-hepatitis, hepatitis adjuvant, anti-tumor, and sugar metabolism; and medical instruments, such as disposable incision retractors, disposable cannula puncture devices disposable specimen extractors, abdominal suction tubes, incision retractor protectors, iodine protective caps, slip pads, respiratory oscillation expectoration machines, protective mask cup types, protective and foldable disposable masks, and medical protective masks. In addition, it offers pharmaceutical packagi…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Huaren Pharmaceutical Co (300110) undervalued?
What is the fair value of 300110?
What is the quality score of 300110?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.